Age

Any age

Sex

MALE

Healthy volunteers

Not accepted

Pathologically confirmed prostatic adenocarcinoma.
Clinically or imaging confirmed metastatic castration resistant prostate cancer.
Conventional treatment failure or not available.
PSMA avid of lesions confirmed by PSMA PET/CT.
Hematopoietic function, kidney and liver function is normal.
Can follow the study plan and can timely follow-up.
Agree to sign the informed consent.

Pathological types other than the prostatic adenocarcinoma of prostate cancer.
Not PSMA avid of lesions confirmed by PSMA PET/CT.
Concurrent with other uncontrolled malignant tumours or five years, except for carcinoma in situ.
Concomitant diseases are not suitable for radioactive therapy.
Other conditions (religion, psychology, etc.) affect the informed consent, research plan, or not compliant of follow-up schedule.

Clinical Trial of Ac225-PSMA Radioligand Therapy of Metastatic Castration-resistant Prostate Cancer